Background

Despite recent evidence that “conservative” oxygenation targets are safe [1, 2], hyperoxia is frequently present in the intensive care unit (ICU) [3, 4]. O2 has friend-and-foe properties because it is vital for ATP production and toxic due to its oxidant effects [5]. On the one hand, “…administration of oxygen should be started immediately to increase O2 delivery…” during the management of circulatory shock in order to counteract the pathognomonic “…imbalance between O2 supply and requirements…” [6]. On the other hand, oxygen toxicity arises from the formation of reactive oxygen species (ROS), in particular during hypoxia/re-oxygenation, e.g., during shock resuscitation. ROS themselves share the janus-headed character of O2: they are vital signaling molecules and their increased release to boost bacterial killing is one of the body’s anti-microbial auto-defense mechanisms [7]. ROS formation is directly related to the PO2 [5] and, hence, O2 was already described as an antibiotic three decades ago [5]. Again, there is contrasting experimental evidence: long-term (48–96 h) exposure to PaO2 values >350–400 mmHg aggravated the pulmonary bacterial burden and the bacteria dissemination [8] due to impaired bacterial phagocytosis and endotoxin-induced cytokine release. Interestingly, ROS scavengers dose-dependently restored the bactericidal capacity.

Hyperoxia during the peri-operative period was reported to reduce post-operative wound infection. Pure O2 ventilation attenuated the anesthesia- and surgery-induced impairment of the phagocytic and microbicidal capacity of alveolar macrophages in healthy patients undergoing prolonged (>6 up to 10 h) elective surgery [9]. The most recent meta-analysis (>8000 patients in 17 randomized control trials (RCTs)) concluded that hyperoxia significantly decreases the risk of surgical site infection during colorectal surgery [10]. Nevertheless, this approach remains highly controversial due to the “moderate evidence” [10] and the deleterious long-term complications reported in patients with cancer [11] and/or cardiovascular disease [12]. Moreover, the question remains unanswered whether hyperoxia affects host defense in mechanically ventilated ICU patients in general: using a multivariate analysis of retrospective data on patients needing mechanical ventilation for >48 h, Six et al. recently identified the number of days with hyperoxia as an independent risk factor of ventilator-associated pneumonia (VAP) [13].

Hyperoxia, lung function, and O2 transport

Hyperoxia impairs pulmonary gas exchange due to inhibition of hypoxic pulmonary vasoconstriction and adsorption atelectasis [5]. Moreover, under healthy conditions blood O2 content only modestly increases upon switching from air to pure O2 breathing due to the near-complete arterial hemoglobin O2 saturation (SaO2) at PaO2 = 90–100 mmHg [5]. Hence, the lower the hemoglobin content, the more pronounced the effect of hyperoxia on blood O2 content, such that hyperoxia may be helpful during hemorrhage [5]. However, any hyperoxia-related rise in blood O2 content may at least in part be counterbalanced by a hyperoxia-induced fall in cardiac output resulting from decreased heart rate and increased systemic vascular resistance, the latter being particularly pronounced in the cerebral and coronary vasculature [5].

The acute hyperoxia-induced impairment of gas exchange must be discriminated from pulmonary O2 toxicity, which presents as pulmonary inflammation and, ultimately, hemorrhagic pulmonary edema [5]. This effect is well-established after long-term hyperoxic exposures and/or when combined with injurious ventilation. The only data in mechanically ventilated patients originate from hyperoxia over 14 h to 30 days and, given the publication year (1972), lung-protective ventilation most likely was not used [5].

Hyperoxia and secondary pulmonary infection

The study by Six et al. [13] clearly suggests an association between hyperoxia and VAP. Of note, hyperoxia was defined as a PaO2 > 120 mmHg, in other words, a PaO2 that is commonly observed in ICU patients [3, 4]. Moreover, the authors showed not only that the numbers of days with hyperoxia, but also “hyperoxemia at ICU admission”, in other words, deliberate, iatrogenic pre-ICU hyperoxia, was an independent risk factor of VAP. Clearly, patients with VAP were older, sicker, and, in particular, more frequently in shock prior to ICU admission. First, shock, as the dysbalance between tissue O2 supply and demand leads to tissue hypoxia, which in turn triggers hyper-inflammation that is aimed to clear pathogens [14]. However, when “too pronounced and/or sustained”, tissue hypoxia may cause anti-inflammation, thereby rendering patients more susceptible to secondary infection [14]. Second, shock is defined as arterial hypotension and/or the need for vasopressor use. Hence, in the study by Six et al., patients with VAP most likely received catecholamines more frequently, for a longer period, and/or at higher doses. Exogenous catecholamines can impair both innate and adaptive immunity and thereby increase bacterial growth and virulence. Despite these potential limits and confounding factors, the study by Six et al. raises an important question with respect to the use of hyperoxia, i.e., whether there is an optimal PaO2 target in the ICU. So far, only retrospective data are available yielding a U-shaped relationship between mortality and arterial PO2, with a nadir at PaO2 values of 110–150 mmHg [3] and 150–200 mmHg [15]. Mortality sharply increased at PaO2 < 65 mmHg and >225 mmHg [3]. However, another study found that even PaO2 > 300 mmHg did not affect outcome, while confirming the harmful impact of PaO2 < 65 mmHg [4]. Consequently, despite a strong signal suggesting an association between hyperoxia and poor hospital outcome, the most recent meta-analyses on hyperoxia [16, 17] are inconclusive due to the high data heterogeneity.

Conclusions

Hyperoxia is common practice during shock management based on experimental evidence that correcting oxygen debt is crucial for survival. On the other hand, oxygen toxicity limits its use, especially during hypoxia/re-oxygenation and/or long-term administration (i.e., >12–24 h). The data of the RCT “Optimal Oxygenation in the Intensive Care Unit (O2-ICU)” (NCT02321072) comparing PaO2 targets of 120 versus 75 mmHg in ICU patients and the detailed results of the preliminary terminated 2 × 2-factorial RCT “Hyperoxia and Hypertonic Saline in Septic Shock (Hyper2S)” (NCT01722422), simultaneously comparing target SaO2 88–95 % versus pure O2 ventilation during the first 24 h and isotonic versus hypertonic saline, are therefore eagerly awaited. The results may allow finding criteria for “…a personalized O2 target…in critically ill patients” [14]. Until then, conservative O2 therapy [1, 2] should be the treatment of choice to avoid both hypoxemia and excess hyperoxia.

Abbreviations

ICU, intensive care unit; RCT, randomized controlled trial; ROS, reactive oxygen species; SaO2, arterial hemoglobin oxygen saturation; VAP, ventilator-associated pneumonia